Pre-clinical studies in ovarian cancer xenograft models have shown increased efficacy for the combination of VEGFR and PDGFR tyrosine kinase inhibitors associated with decreased vessel coverage by pericytes supporting PDGF signalling as an antiangiogenic therapeutic target (Lu et al, 2007). This evidence concerns the gene KDR and ovarian cancer.